Bulletin from Egetis Therapeutics’ Annual General Meeting 2023

April 27, 2023

Stockholm, Sweden, April 27, 2023. Egetis Therapeutics AB (publ) (STO: EGTX) today announced that the Annual General Meeting (AGM) has been held on April 27, 2023, at which the submitted proposals were passed. The complete proposals are stated in the notice to the Annual General Meeting.

The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). Among other items of business, the following resolutions were taken:
The income statements and balance sheets were adopted, together with the Board of Directors' proposal for allocation of the company’s result. The Board of Directors and CEO were discharged from liability for the financial year 2022.

Thomas Lönngren, Mats Blom, Gunilla Osswald, Elisabeth Svanberg and Peder Walberg were re-elected and Behshad Sheldon was newly elected as members of the Board of Directors. Thomas Lönngren was re-elected as Chairman of the Board of Directors.

The Annual General Meeting voted on the Board of Directors’ fees in accordance with the Nomination Committee’s proposal as follows:
It was resolved that remuneration shall be paid with SEK 630,000 for the Chairman of the Board of Directors, SEK 235,000 for other Board members not employed by the company and that no remuneration be paid to Board members who are employed by the company. Furthermore, SEK 80,000 shall be paid to the chairman of the audit committee and SEK 40,000 to each other member of the audit committee. Furthermore, SEK 50,000 shall be paid to the chairman of the remuneration committee and SEK 25,000 to each other member of the remuneration committee. Finally, SEK 80,000 shall be paid to the chairman of the Market Access committee and SEK 40,000 to each other member of the Market Access committee.

It was resolved to elect the registered accounting firm Öhrlings PricewaterhouseCoopers AB (PwC) as auditor. Authorized public accountant Leonard Daun will assume the role as auditor in charge.

The Nomination Committee´s proposal regarding the establishment of a Nomination Committee and Nomination Committee instructions was approved.

The Annual General Meeting approved the Board of Directors’ remuneration report for 2022.

The Annual General Meeting approved the proposal from the Board of Directors regarding the introduction of a long-term incentive program for the company’s management and key personnel.

The Annual General Meeting voted, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to issue shares, warrants and/or convertibles.

Minutes with complete resolutions from the Annual General Meeting will be made available on the Company´s website, www.egetis.com

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
The Company’s lead drug candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum thyroid hormone T3 levels and secondary clinical endpoints. As a result of regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) during the second quarter of 2023 based on existing clinical data.
After a dialogue with the FDA, Egetis will conduct a small randomized, placebo-controlled study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis intends to submit a new drug application (NDA) in the US for Emcitate in the fourth quarter of 2023 under the Fast-Track Designation granted by FDA.
Emcitate is currently being investigated in the Triac Trial II, a Phase II/III study in very young MCT8 deficiency patients (<30 months of age) exploring potential disease modifying effects of early intervention from a neurocognitive and neurodevelopmental perspective. The recruitment target was achieved in the second quarter 2022 and 22 patients have been included in the study. Results are expected in mid 2024 and are expected to be submitted post-approval to regulatory authorities shortly thereafter.
Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Emcitate has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.
The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase Iib/III study with the purpose of applying for market approval in the US and Europe for Aladote has been finalized after completed interactions with FDA, EMA and MHRA and study start is planned during 2023. Aladote has been granted ODD in the US and in the EU.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

Bulletin from Egetis Therapeutics’ Annual General Meeting 2023

Contact us